Media coverage about ObsEva (NASDAQ:OBSV) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ObsEva earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.3235389158316 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
OBSV has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of ObsEva in a research report on Wednesday, November 8th. Royal Bank of Canada reissued a “buy” rating and set a $22.00 target price on shares of ObsEva in a research report on Thursday, November 2nd. BMO Capital Markets started coverage on ObsEva in a research report on Monday, December 4th. They set an “outperform” rating and a $20.00 target price on the stock. Zacks Investment Research upgraded ObsEva from a “sell” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Wednesday, October 18th. Finally, Credit Suisse Group started coverage on ObsEva in a research note on Monday, October 9th. They set an “outperform” rating and a $16.00 price target on the stock. Seven analysts have rated the stock with a buy rating, ObsEva currently has a consensus rating of “Buy” and a consensus target price of $19.00.
Shares of ObsEva (NASDAQ OBSV) opened at $9.82 on Wednesday. ObsEva has a 1 year low of $5.00 and a 1 year high of $14.69.
ObsEva (NASDAQ:OBSV) last issued its earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.01). The firm’s quarterly revenue was up NaN% compared to the same quarter last year. analysts forecast that ObsEva will post -2.27 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/12/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-obseva-obsv-stock-price.html.
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.